摘要:
The present invention relates to a therapeutic agent for diabetes with sulfonylurea secondary failure, which contains a GPR40 agonist. According to the present invention, a therapeutic agent for diabetes with sulfonylurea secondary failure that affords a superior insulin secretion effect and a superior hypoglycemic effect even in diabetic patients for whom a sulfonylurea compound or a fast-acting insulin secretagogue fails to provide an insulin secretion effect and therefore, fails to provide a sufficient hypoglycemic effect can be provided.
摘要:
A first motor 3 and a second motor 4 of variable displacement type are in parallel to each other connected to a hydraulic pump 2 in a closed circuit, through which the output torque from the first motor 3 is transmitted to an output shaft 6. A clutch control unit 10 controls a clutch device 15 as: when the engine speed is N1, which is the case where the accelerator pedal is fully depressed, the clutch is disengaged at the vehicle speed v1. When the engine speed is N3(
摘要:
There are provided: a first circuit for traveling HC1, formed through a closed circuit connection of a variable displacement hydraulic pump 2 and a variable displacement hydraulic motor 3, that includes a motor control unit 10, 11 that controls a displacement of the hydraulic motor 3; a second circuit for working HC2 that drives a work hydraulic actuator 114, 115 by pressure oil from a work hydraulic pump 4; and a maximum value control unit 10 that controls a maximum displacement of the hydraulic motor 3 in accordance with load pressure Pf in the second circuit HC2. The maximum value control unit 10 decreases the maximum displacement to a minimum limit q1 corresponding to a maximum load pressure Pr in the second circuit when load pressure Pf in the second circuit exceeds a predetermined value Ps.
摘要:
The present invention relates to a therapeutic agent for diabetes with sulfonylurea secondary failure, which contains a GPR40 agonist. According to the present invention, a therapeutic agent for diabetes with sulfonylurea secondary failure that affords a superior insulin secretion effect and a superior hypoglycemic effect even in diabetic patients for whom a sulfonylurea compound or a fast-acting insulin secretagogue fails to provide an insulin secretion effect and therefore, fails to provide a sufficient hypoglycemic effect can be provided.
摘要:
A melanin-concentrating hormone antagonist which comprises a compound of the formula: wherein Ar1 is a cyclic group which may have substituents; X is a spacer having a main chain of 1 to 6 atoms; Y is a bond or a spacer having a main chain of 1 to 6 atoms; Ar is a monocyclic aromatic ring which may be condensed with a 4 to 8 membered non-aromatic ring, and may have further substituents; R1 and R2 are independently hydrogen atom or a hydrocarbon group which may have substituents; R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; R2 may form a spiro ring together with Ar; or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents; or a salt thereof; which is useful as an agent for preventing or treating obesity, etc.
摘要翻译:一种黑色素浓缩激素拮抗剂,其包含下式化合物:其中Ar 1是可以具有取代基的环状基团; X是具有1至6个原子的主链的间隔物; Y是具有1至6个原子的主链的键或间隔基; Ar是可以与4至8元非芳族环稠合的单环芳环,并且可以具有其它取代基; R 1和R 2独立地是氢原子或可以具有取代基的烃基; R 1和R 2与相邻的氮原子一起可以形成可以具有取代基的含氮杂环; R 2可以与Ar一起形成螺环; 或R 2连同相邻的氮原子和Y可以形成可具有取代基的含氮杂环; 或其盐; 其可用作预防或治疗肥胖症等的药剂。
摘要:
The present invention relates to (1) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:7 (A chain), (2) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:8 (B chain), (3) a polypeptide wherein the A and B chains are bonded to each other via disulfide bonds (2 chains) or its salt, (4) DNAs encoding the same, etc. These polypeptides and DNAs encoding the same can be used for the diagnosis, treatment, prevention, etc. for diseases, including abnormalities (e.g., diabetes mellitus, etc.) in metabolic regulation (sugar metabolism, lipid metabolism, etc.) of energy sources such as carbohydrates.
摘要翻译:本发明涉及(1)含有与SEQ ID NO:7(A链)所示氨基酸序列相同或基本相同的氨基酸序列的多肽,(2)含有相同或基本相同氨基的多肽 酸序列作为由SEQ ID NO:8(B链)表示的氨基酸序列,(3)其中A和B链通过二硫键(2链)或其盐彼此键合的多肽,(4)DNA 编码相同的这些多肽和DNA可用于诊断,治疗,预防等疾病,包括代谢调节异常(如糖尿病等)(糖代谢,脂质代谢, 等等)的能源,如碳水化合物。
摘要:
The sustained-release preparation of the present invention, which contains a dipeptidyl peptidase IV inhibitor and a hydrophilic polymer, can appropriately inhibit the DPP-IV activity, and is superior in convenience or compliance.
摘要:
The present invention provides a method for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, characterized by using MCH or its derivative or a salt thereof and SLC-1 or its salt is useful for screening an SLC-1 agonist which can be used not only as an appetite (eating) promoting agent but also as a prophylactic/therapeutic agent for weak pains, atonic bleeding, before and after expulsion, subinvolution of uterus, cesarean section, induced abortion, galactostasis, and the like, and an SLC-1 antagonist which can be used not only as an antiobestic agents (drug), an appetite (eating) modulator, and the like, but also as a prophylactic/therapeutic agent for hyperstimulation, ankylosing uterine contractions, fetal distress, uterine rupture, cervical laceration, preterm delivery, Prader-Wili syndrome and the like.
摘要:
A melanin-concentrating hormone antagonist comprising a compound of the formula (I): wherein Ar1 is a cyclic group which may be substituted; X and Y are the same or different and are a spacer having a main chain of 1 to 6 atoms; Ar is a condensed polycyclic aromatic ring which may be substituted; R1 and R2 are the same or different and are hydrogen atom or a hydrocarbon group which may be substituted; or R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted; or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted; or R2, together with the adjacent nitrogen atom, Y and Ar, may form a condensed ring; or a salt thereof is useful as an agent for preventing or treating obesity, etc.
摘要:
A testing apparatus (10) is provided to securely detect a mounting error of a fittable member (5) on a connector (1). The testing apparatus (10) has a testing unit (20) for detecting an ajar state of the fittable member (5) on a housing (2) of a connector (1). The testing unit (20) is provided with an elastic contact (22) for elastically contacting the housing (2) of the connector I1) along locking direction (Y) in which the fittable member (5) is locked with the housing (2). This elastic contact (22) is provided with a switch (23) for detecting the ajar state of the fittable member (5) at a contact position of the elastic contact (22) with the housing (2).